Menzies-Gow, AndrewHoyte, Flavia L.Price, DavidCohen, DavidBarker, PeterKreindler, JamesJison, MariaBrooks, Christopher L.Papeleu, PeggyKatial, Rohit2022-05-052022-05-052022-05-01Menzies-Gow, A, Hoyte, F L, Price, D, Cohen, D, Barker, P, Kreindler, J, Jison, M, Brooks, C L, Papeleu, P & Katial, R 2022, 'Clinical Remission in Severe Asthma : A Pooled Post hoc Analysis of the Patient Journey with Benralizumab ', Advances in Therapy, vol. 39, no. 5, pp. 2065–2084. https://doi.org/10.1007/s12325-022-02098-10741-238Xhttps://hdl.handle.net/2164/18523Funding This study, the Rapid Service Fee, and the Open Access Fee were funded by AstraZeneca (Gaithersburg, MD, USA).201454603engBenralizumabBiologic therapiesOral corticosteroids (OCS)Precision medicineRemissionSevere eosinophilic asthmaSuper-responseTreat-to-targetR MedicineSupplementary InformationSupplementary DataRJournal article10.1007/s12325-022-02098-1395